Global Biomarker Discovery Outsourcing Services Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Biomarker Discovery Outsourcing Services Market Evolve From 2026 To 2030?
The market size for biomarker discovery outsourcing services has experienced rapid expansion in recent years. This market is expected to increase from $16.96 billion in 2025 to $19.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.4%. The historical growth trajectory can be attributed to factors like increasing pharmaceutical r&d spending, expansion of personalized medicine research, rising complexity of drug development pipelines, growing use of biomarkers in oncology trials, and the availability of specialized outsourcing providers.
The biomarker discovery outsourcing services market is projected to experience swift expansion in the coming years. This market is forecast to reach $33.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. Factors contributing to this growth during the forecast period include the rising acceptance of precision medicine strategies, an increasing need for early disease identification instruments, the expansion of clinical trials driven by biomarkers, the expanding application of AI-powered biomarker analytics, and enhanced regulatory approval for biomarker endpoints. Key trends anticipated for the forecast period encompass the wider embrace of multi-omics biomarker platforms, an escalating demand for predictive and prognostic biomarkers, increased utilization of outsourced biomarker validation services, an expansion in the development of companion diagnostics, and a heightened emphasis on integrating biomarkers into clinical trials.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15741&type=smp
What Drivers Are Influencing The Biomarker Discovery Outsourcing Services Market?
The escalating emphasis on personalized medicine is projected to stimulate the growth of the biomarker discovery outsourcing services market in the future. Personalized medicine involves customizing medical treatment to suit the unique characteristics of each patient. This rise in personalized medicine stems from individual genetic, lifestyle, and environmental influences, which yield precise healthcare outcomes, ultimately improving patient care and reducing adverse effects. Outsourcing biomarker discovery services plays a crucial role in advancing personalized medicine by delivering tailored diagnostic and therapeutic solutions, which are based on individual patients’ biological markers. For instance, a report released in February 2024 by the Personalized Medicine Coalition, a US-based organization, revealed that in 2023, the FDA gave its approval to 16 new personalized treatments for rare disease patients, marking an increase from six in 2022. The personalized treatments newly approved in 2023 comprised seven cancer drugs and three for other diseases and conditions. Thus, the growing focus on personalized medicine is a key driver for the expansion of biomarker discovery outsourcing services.
Which Segment Areas Are Covered In The Biomarker Discovery Outsourcing Services Market Analysis?
The biomarker discovery outsourcing services market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints
2) By Discovery Phase: Biomarker Identification, Biomarker Validation, Biomarker Profiling, Biomarker Panel Development, Biomarker Selection
3) By Therapeutic Area: Oncology, Cardiology, Neurology, Autoimmune Diseases, Other Therapeutic Areas
4) By End Use: Pharmaceutical Companies, Biotechnology Companies
Subsegments:
1) By Predictive Biomarkers: Disease Risk Assessment, Therapy Response Prediction, Personalized Medicine Guidance
2) By Prognostic Biomarkers: Disease Progression Prediction, Patient Survival Forecast, Recurrence Risk Assessment
3) By Safety Biomarkers: Toxicity Prediction, Drug Safety Evaluation, Adverse Effect Risk Assessment
4) By Surrogate Endpoints: Clinical Trial Outcome Indicators, Disease Progression Monitoring, Therapy Efficacy Tracking
Which Trends Are Shaping The Future Of The Biomarker Discovery Outsourcing Services Market?
Leading companies in the biomarker discovery outsourcing services market are prioritizing the development of multiplexed biomarker assays, such as the immunoproteomic discovery platform, to enhance patient outcomes and advance the field of biomarker identification. An immunoproteomic discovery platform functions as a specialized system that merges immunology and proteomics to pinpoint and analyze proteins associated with the immune response. For example, in October 2023, Sengenics Corporation LLC, a precision medicine company based in Singapore, launched its immunoproteomic discovery platform, which is a comprehensive protein microarray platform designed for the analysis of autoantibodies linked to disease diagnosis and therapeutic interventions. The i-Ome Discovery platform was created to further immune biomarker discovery and development and to support academic and clinical biopharmaceutical research teams aiming for a better understanding of the dynamic interactions and relationships among proteins, the immune system, and disease.
Which Global Companies Are Actively Competing In The Biomarker Discovery Outsourcing Services Market?
Major companies operating in the biomarker discovery outsourcing services market are Charles River Laboratories International Inc, Evotec SE, WuXi AppTec Co. Ltd, Precision for Medicine Inc, SomaLogic Inc, Metabolon Inc, Caprion Proteomics Inc, Crown Bioscience Inc, Selvita S.A., Frontage Laboratories Inc, BioAgilytix Labs LLC, Discovery Life Sciences LLC, Labcorp Drug Development Inc, Parexel International Corporation, ICON plc, Medpace Inc, Syneos Health Inc, Celerion Inc, Canopy Biosciences LLC, BioIVT LLC, Intertek Group plc, Eurofins Scientific SE
Read the full biomarker discovery outsourcing services market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Biomarker Discovery Outsourcing Services Market?
North America was the largest region in the biomarker discovery outsourcing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker discovery outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Biomarker Discovery Outsourcing Services Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15741&type=smp
Browse Through More Reports Similar to the Global Biomarker Discovery Outsourcing Services Market 2026, By The Business Research Company
Biomarker Clinical Phase Outsourcing Services Global Market Report
Biomarkers Global Market Report
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Clinical Biomarkers Global Market Report
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
